(A) MDMs were treated with 100 μg/ml MDP for 4h, or pre-treated for 48h, washed, and left untreated or restimulated for an additional 4h with MDP. Fold change MT isoform mRNA+SEM (n=8; each subject served as their own control). (B) Fold change IL-6, IL-8 and TNF mRNA+SEM. Representative western blot for (C) total MT-1/2 (n=4), and (D) (top) MT-1A and (bottom) MT-1B/H/X (n=4) in MDMs treated with 100 μg/ml for the indicated times. (E) MT-1G, MT-1M and MT-1X mRNA expression was assessed in untreated human ileal myeloid-derived cells (n=8) and peripheral MDMs (n=8). Pretx, pre-treatment; Tx, treatment; M, MDP. Significance between treated compared to untreated or select conditions as indicated. *, p<0.05; **, p<0.01; ***, p<0.001.